Aurum Biosciences Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Latest Deal Amount
  • $13.4M

  • Investors
  • 6

Aurum Biosciences General Information

Description

Developer of novel pharmaceuticals designed for patients with acute ischaemic stroke. The company's pharmaceuticals carry and deliver oxygen independent of hemoglobin and have the potential to be used in multiple indications where oxygen is required, enabling physicians to provide safe therapy that can be given irrespective of the time window.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Imaging Centre of Excellence
  • Queen Elizabeth University Hospital Campus, Langlands Road
  • Glasgow G51 4LB
  • Scotland, United Kingdom
+44 07711
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Imaging Centre of Excellence
  • Queen Elizabeth University Hospital Campus, Langlands Road
  • Glasgow G51 4LB
  • Scotland, United Kingdom
+44 07711

Aurum Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurum Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) $13.4M In Progress Generating Revenue
6. Later Stage VC 30-Aug-2025 Completed Generating Revenue
5. Later Stage VC 18-Jan-2024 Completed Clinical Trials - Phase 2
4. Later Stage VC 25-Sep-2020 Completed Clinical Trials - Phase 2
3. Later Stage VC 01-Sep-2015 Completed Startup
2. Angel (individual) Completed Startup
1. University Spin-Out 01-Nov-2010 Completed Startup
To view Aurum Biosciences’s complete valuation and funding history, request access »

Aurum Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary
Ordinary
Ordinary 790,307 $0.000134 $1.15 $1.15 1x $1.15 25.34%
Ordinary 1,007,000 $0.000134 $1.34 $1.34 1x $1.34 32.29%
To view Aurum Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aurum Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel pharmaceuticals designed for patients with acute ischaemic stroke. The company's pharmaceuticals carr
Drug Discovery
Glasgow, United Kingdom
5 As of 2026

Cambridge, MA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aurum Biosciences Competitors (55)

One of Aurum Biosciences’s 55 competitors is GentiBio, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GentiBio Venture Capital-Backed Cambridge, MA
Endeavor BioMedicines Venture Capital-Backed San Diego, CA
American Gene Technologies Venture Capital-Backed Rockville, MD
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Apeptico Formerly VC-backed Vienna, Austria
You’re viewing 5 of 55 competitors. Get the full list »

Aurum Biosciences Patents

Aurum Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2925223-A1 Improved methods of assessing metabolic function Active 27-Nov-2012
EP-2925223-B1 Improved methods of assessing metabolic function Active 27-Nov-2012
US-20150313540-A1 Improved methods of assessing metabolic function Active 27-Nov-2012
ES-2933929-T3 Improved methods to assess metabolic function Active 27-Nov-2012
US-10278642-B2 Methods of assessing metabolic function Active 27-Nov-2012 A61B5/4866
To view Aurum Biosciences’s complete patent history, request access »

Aurum Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aurum Biosciences Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Infinion Biopharma Investment Bank Minority
InnoScot Health Corporation Minority
Scottish Enterprise Growth/Expansion Minority
TRICAPITAL Angel Investors Angel Group Minority
Wellcome Trust Limited Partner Minority
You’re viewing 5 of 6 investors. Get the full list »

Aurum Biosciences FAQs

  • When was Aurum Biosciences founded?

    Aurum Biosciences was founded in 2010.

  • Where is Aurum Biosciences headquartered?

    Aurum Biosciences is headquartered in Glasgow, United Kingdom.

  • What is the size of Aurum Biosciences?

    Aurum Biosciences has 5 total employees.

  • What industry is Aurum Biosciences in?

    Aurum Biosciences’s primary industry is Drug Discovery.

  • Is Aurum Biosciences a private or public company?

    Aurum Biosciences is a Private company.

  • What is Aurum Biosciences’s current revenue?

    The current revenue for Aurum Biosciences is .

  • How much funding has Aurum Biosciences raised over time?

    Aurum Biosciences has raised $3.75M.

  • Who are Aurum Biosciences’s investors?

    Infinion Biopharma, InnoScot Health, Scottish Enterprise, TRICAPITAL Angel Investors, and Wellcome Trust are 5 of 6 investors who have invested in Aurum Biosciences.

  • Who are Aurum Biosciences’s competitors?

    GentiBio, Endeavor BioMedicines, American Gene Technologies, Inovio Pharmaceuticals, and Apeptico are some of the 55 competitors of Aurum Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process